
    
      This is a randomized, double-blind, parallel group, multicenter study to compare the
      pharmacokinetics (PK), pharmacodynamics (PD), safety, efficacy, tolerability, and
      immunogenicity of SAIT101 (biosimilar rituximab) versus MabThera® versus Rituxan® in patients
      with rheumatoid arthritis (RA). This study will take place globally across approximately 75
      study centers in order to randomize approximately 282 patients. The study consists of Part A
      from baseline for PK and efficacy analysis, followed by Part B from Week 24 to 52 for safety
      follow-up in which collects transition data.
    
  